Interestingly, MALDI-IMS indicated not only a positive correlation between the severity of L-DOPA-induced dyskinesia and the nigral levels of dynorphin B and alpha-neoendorphin, but also that the most significant differences were localized to the lateral substantia nigra [83], suggesting possible mechanisms that might be amenable to targeted treatment. This evidence concerns the gene PDYN and drug-induced dyskinesia.